SCHEMBL9918150

SCHEMBL9918150

CS(=O)(=O)OC1CCN(P)C1

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8487018 1.00 HRH3 (0.32) HRH3
SCHEMBL13009946 0.83 PIM1 (0.31)
SCHEMBL1108992 0.78 CHRM4 (0.38) HRH3
SCHEMBL1928299 0.78 CHRM4 (0.38) HRH3
SCHEMBL8540600 0.76 TP53 (0.42) HRH3
SCHEMBL8540595 0.76 TP53 (0.42) HRH3
SCHEMBL8540599 0.76 TP53 (0.42) HRH3
SCHEMBL1928159 0.74 KDM4E (0.33) HRH3
SCHEMBL4532348 0.73 ATM (0.38) HRH3
SCHEMBL1928262 0.73 HRH3 (0.37) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11660286-B2 Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products EPICENTRX, INC. (US) 2023-05-30 US disclosed
US-9468625-B2 Organonitro thioether compounds and medical uses thereof EPICENTRX, INC. (US) 2016-10-18 US disclosed
US-20160081981-A1 ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF RADIORX, INC. 2016-03-24 US disclosed
US-9139519-B2 Organonitro thioether compounds and medical uses thereof EPICENTRX, INC. (US) 2015-09-22 US disclosed
US-20140349988-A1 ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF RADIORX, INC. (US) 2014-11-27 US disclosed
US-20140308260-A1 METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS EPICENTRX, INC. 2014-10-16 US disclosed
US-8242286-B2 Phenoxy-pyrrolidine derivative and its use and compositions MEDICIS PHARMACEUTICAL CORPORATION (US) 2012-08-14 US disclosed
US-20120149678-A1 Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto ORONSKY BRYAN T (US) 2012-06-14 US disclosed
US-20100247471-A1 PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS GRACEWAY PHARMACEUTICALS, LLC (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100247471-A1 PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS SCD, SCD5, FADS2 HRH3 4215/4885
US-11660286-B2 Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products HBB, HBG2, HBZ HRH3 1728/4885
US-20120149678-A1 Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto NPM1, MCL1, BCL9 HRH3 3110/4885
US-20140308260-A1 METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS HBB, HBG2, HBZ HRH3 1728/4885
US-20140349988-A1 ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF SLC22A8, SLCO2A1, SLCO2B1 HRH3 4150/4885
US-20160081981-A1 ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF SLC22A8, XPOT, NPM1 HRH3 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.